Inosine
CAS 58-63-9
Inosine (CAS 58-63-9) is a Phase 3 pharmaceutical compound with 3 bioactivity targets and 6 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 5983.17 nM | 10 | - |
| - | AC50 | 13037.9 nM | 3 | - |
| - | IC50 | 13317.616666666667 nM | 2 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Inosine used for in pharmaceutical contexts?
Inosine (CAS 58-63-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Inosine?
Inosine has 6 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Drug ineffective, Infection, Nasopharyngitis, Off label use, Rheumatoid arthritis. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Inosine also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Inosine with EU status "permitted".
What clinical phase is Inosine in?
Inosine is rendered with ChEMBL max phase 3.